HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, is proud to announce the successful issuance of a patent from the European Patent Office. This patent enables the HeartBeam AIMIGo™ credit card-sized device to generate a synthesized 12-lead ECG, and provides protection for HeartBeam’s flagship technology in multiple countries in Europe. With this revolutionary innovation, patients are now able to record a set of signals with the AIMIGo and send an immediate diagnostic 12-lead ECG to their physician for review and diagnosis, without ever having to enter a medical setting.
Cardiovascular disease (CVD) is the leading cause of death in Europe and a major cause of morbidity. Every year, over 11 million new cases of CVD occur, affecting almost 49 million people in the EU at a staggering cost of €210 billion. Unfortunately, no current single-lead ECG product is capable of detecting a heart attack. HeartBeam is here to change that. Our revolutionary technology is the world’s first 12-lead ECG solution that fits in a wallet, giving users the power to detect a heart attack anytime, anywhere.
HeartBeam CEO and Founder Branislav Vajdic, Ph.D. is excited to announce that the company’s initial European patent has been granted, granting them further protection for their HeartBeam AIMIGo technology. This technology offers 12-lead ECG capability, and as HeartBeam expands its product applications to reach a variety of regions in the global marketplace, the intellectual property protection provided by this patent will be essential.
HeartBeam’s newly granted 12-lead ECG patch patent (No. EP3280326) is a game-changer for cardiac patients. It promises to reduce the fear of chest pain and give them peace of mind with long-term, continuous monitoring. This is made possible by HeartBeam’s breakthrough technology, which allows patients to get a 12-lead ECG anytime, anywhere. The AIMIGo solution furthers this by always being with the patient and providing timely heart attack intervention. This could significantly increase the quality of life for cardiac patients.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is revolutionizing the way heart attacks are detected with their groundbreaking 3D-vector ECG platform. By using a suite of proprietary algorithms to analyze VECG data, their platform is able to help clinicians determine if a patient is having a heart attack quickly and accurately. HeartBeam has two patented products in development, AIMI™ and AIMIGo™, that respectively provide 3D comparison of baseline and symptomatic 12-lead ECG for acute care settings and a credit card-sized 12-lead output ECG device with a smart phone app and cloud-based diagnostic software system. Although not yet cleared by the US FDA, these products have the potential to revolutionize cardiac care and save lives.
As we move forward, there are inherent risks and uncertainties that may cause actual results to differ from our expectations. We encourage you to consider these risks and uncertainties when evaluating our forward-looking statements. To ensure that our forward-looking statements are accurate, we will keep you updated on any changes in our expectations or any changes in events, conditions, or circumstances that may affect our statements. We are committed to keeping you informed and urge you not to place too much reliance on any forward-looking statements.